Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
HOME > BUSINESS
BUSINESS
- Chugai Succeeds in Establishing World's First Stable Cancer Stem Cell Lines
October 22, 2012
- MTPC to Dissolve Capital Alliance with Choseido
October 22, 2012
- Kyowa Kirin Suspends PIIa Study of RTA 402 in Response to Licensor’s Termination of Study
October 22, 2012
- Nexium Dominates No.1, 2 Positions in Both GP, HP Markets in September Prior to Lifting of Ban on Long-Term Prescription: RepTrack Survey
October 19, 2012
- 40% of Doctors Collect Drug Information Via Smartphones: CareNet Survey
October 19, 2012
- Novartis Files for Additional Indication of Pediatric Use for Xolair
October 18, 2012
- Ajinomoto Files NDA for AJH801, 6th Fixed-Dose ARB/CCB Combination in Japan
October 18, 2012
- Qol’s Mr Takada Hints at Continued Use of Long-Listed Drugs from Makers Hiring Apo Plus MRs
October 17, 2012
- Asklep to Set Up 3rd East Asian Subsidiary in South Korea
October 17, 2012
- Denosumab Significantly Reduces Vertebral Fractures in Osteoporosis Patients in PIII Study: Daiichi Sankyo
October 17, 2012
- Asahi Glass Offers CMO Services to Biopharmaceutical Industry Using ASPEX Technology: Dr Kumagai
October 17, 2012
- MediciNova to Bring Japanese Pharma Synthesized Drug Candidates to the World: Dr Matsuda
October 17, 2012
- Qol to Fully Enter CSO Market thru Apo Plus Acquisition, Mr Takada to Be Director
October 16, 2012
- MTPC’s Oral MS Treatment Charging towards Blockbuster Territory
October 16, 2012
- Hospira Files Public Knowledge-Based Application for Generic Gemcitabine for Malignant Lymphoma
October 16, 2012
- Towa Pharmaceutical Expanding Direct-Sales Network as Its Distributors Face Lack of Successors
October 15, 2012
- Pirespa Debuts in South Korea through Ildong: Shionogi
October 15, 2012
- Long-Term Investments in Developing Countries Expects Returns from 2020: President Naito of Eisai
October 15, 2012
- Radical AD Treatments Hit “PIII Wall” Again, but Amyloid β Hypothesis Remains Unshaken
October 15, 2012
- Meiji Seika Pharma to Solely Market 3 Diagnostics for Infectious Diseases
October 12, 2012
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…